Accentia reiterated at buy by Jefferies

Accentia Biopharmaceuticals, Inc. was reiterated by Jefferies & Co., Inc. analyst Adam Walsh at buy. Jefferies lowered its price target to $9 from $11. While disappointed that Emezine for the treatment of nausea and vomiting was not approved by the Food and Drug Administration, the analyst believes Accentia's opportunity lies with SimuNase. Shares of the Tampa, Fla., biopharmaceutical company were down 61 cents, or 8.08%, at $6.94 on volume of 24,000 shares versus the three-month running average of 57,916 shares. (Nasdaq: ABPI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.